Development of dual inhibitors against Alzheimer's disease using fragment-based QSAR and molecular docking

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Goyal, Manisha ^a   Dhanjal, Jaspreet Kaur ^b   Goyal, Sukriti ^a   Tyagi, Chetna ^b   Hamid, Rabia ^c   Grover, Abhinav ^b  

^a BANASTHALI UNIVERSITY   (India)

^b JAWAHARLAL NEHRU UNIVERSITY   (India)

^c UNIVERSITY OF KASHMIR   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDROPYRIDINE DERIVATIVE; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; BETA SECRETASE 1; 1,4-DIHYDROPYRIDINE; ACHE PROTEIN, HUMAN; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; DIHYDROPYRIDINE DERIVATIVE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; PROTEIN BINDING; SECRETASE;

ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; COMBINATORIAL LIBRARY; DRUG STRUCTURE; ENZYME INHIBITION; HIGH TEMPERATURE; MOLECULAR DOCKING; MOLECULE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; ROOM TEMPERATURE; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; COMBINATORIAL CHEMISTRY; HUMAN; METABOLISM; PROCEDURES;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ACID ENDOPEPTIDASES; BINDING SITES; COMBINATORIAL CHEMISTRY TECHNIQUES; DIHYDROPYRIDINES; GPI-LINKED PROTEINS; HUMANS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84903625019     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/979606     Document Type: Article

References (43)

1. Benzi G., Moretti A., Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease? European Journal of Pharmacology 1998 346 1 1 13 2-s2.0-0032478778 10.1016/S0014-2999(98) 00093-4 (Pubitemid 28197082)
2. Belluti F., Bartolini M., Bottegoni G., Bisi A., Cavalli A., Andrisano V., Rampa A., Benzophenone-based derivatives: a novel series of potent and selective dual inhibitors of acetylcholinesterase and acetylcholinesterase- induced beta-amyloid aggregation. European Journal of Medicinal Chemistry 2011 46 5 1682 1693 2-s2.0-79953214018 10.1016/j.ejmech.2011.02.019
3. Walsh D. M., Selkoe D. J., Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004 44 1 181 193 2-s2.0-5344277556 10.1016/j.neuron.2004.09.010 (Pubitemid 39348839)
4. Choi S.-J., Cho J.-H., Im I., Lee S.-D., Jang J.-Y., Oh Y.-M., Jung Y.-K., Jeon E.-S., Kim Y.-C., Design and synthesis of 1,4-dihydropyridine derivatives as BACE-1 inhibitors. European Journal of Medicinal Chemistry 2010 45 6 2578 2590 2-s2.0-77950811650 10.1016/j.ejmech.2010.02.046
5. Klafki H.-W., Staufenbiel M., Kornhuber J., Wiltfang J., Therapeutic approaches to Alzheimer's disease. Brain 2006 129 11 2840 2855 2-s2.0-33750582961 10.1093/brain/awl280 (Pubitemid 44684507)
6. Edwards P. D., Albert J. S., Sylvester M., Aharony D., Andisik D., Callaghan O., Campbell J. B., Carr R. A., Chessari G., Congreve M., Frederickson M., Folmer R. H. A., Geschwindner S., Koether G., Kolmodin K., Krumrine J., Mauger R. C., Murray C. W., Olsson L.-L., Patel S., Spear N., Tian G., Application of fragment-based lead generation to the discovery of novel, cyclic amidine β -secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. Journal of Medicinal Chemistry 2007 50 24 5912 5925 2-s2.0-37849043411 10.1021/jm070829p
7. Aguzzi A., O'Connor T., Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nature Reviews Drug Discovery 2010 9 3 237 248 2-s2.0-77649202326 10.1038/nrd3050
8. Kelly C. A., Harvey R. J., Cayton H., Drug treatments for Alzheimer's disease. British Medical Journal 1997 314 7082 693 694 (Pubitemid 27113069)
9. Whitehouse P. J., Cholinergic therapy in dementia. Acta Neurologica Scandinavica, Supplement 1993 88 149 42 45 2-s2.0-0027741511 (Pubitemid 24027491)
10. Scott L. J., Goa K. L., Galantamine: a review of its use in Alzheimer's disease. Drugs 2000 60 5 1095 1122 2-s2.0-0033668050
11. Yan A., Wang K., Quantitative structure and bioactivity relationship study on human acetylcholinesterase inhibitors. Bioorganic & Medicinal Chemistry Letters 2012 22 9 3336 3342 10.1016/j.bmcl.2012.02.108
12. Birks J., Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews 2006 1 CD005593 2-s2.0-33645524717
13. Areosa S. A., Sherriff F., McShane R., Memantine for dementia. Cochrane Database of Systematic Reviews 2006 2 CD003154 2-s2.0-21844469511
14. Weiner M. W., Sadowsky C., Saxton J., Hofbauer R. K., Graham S. M., Yu S. Y., Li S., Hsu H.-A., Suhy J., Fridman M., Perhach J. L., Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer's disease. Alzheimer's and Dementia 2011 7 4 425 435 2-s2.0-79960836273 10.1016/j.jalz.2010.09.003
15. Selkoe D. J., Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999 399 supplement A23 A31 2-s2.0-0033600274
16. Guo T., Hobbs D. W., Development of BACE1 inhibitors for Alzheimer's disease. Current Medicinal Chemistry 2006 13 15 1811 1829 2-s2.0-33745052352 10.2174/092986706777452489 (Pubitemid 43871758)
17. Piazzi L., Cavalli A., Colizzi F., Belluti F., Bartolini M., Mancini F., Recanatini M., Andrisano V., Rampa A., Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorganic & Medicinal Chemistry Letters 2008 18 1 423 426 2-s2.0-37549066630 10.1016/j.bmcl.2007.09.100
18. Cavalli A., Bolognesi M. L., Mìnarini A., Rosini M., Tumiatti V., Recanatini M., Melchiorre C., Multi-target-directed ligands to combat neurodegenerative diseases. Journal of Medicinal Chemistry 2008 51 3 347 372 2-s2.0-39149091398 10.1021/jm7009364 (Pubitemid 351252260)
19. Piazzi L., Rampa A., Bisi A., Gobbi S., Belluti F., Cavalli A., Bartolini M., Andrisano V., Valenti P., Recanatini M., 3-(4-{[benzyl(methyl)amino]methyl} -phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced β -amyloid aggregation: a dual function lead for Alzheimer's disease therapy. Journal of Medicinal Chemistry 2003 46 12 2279 2282 2-s2.0-12444257779 10.1021/jm0340602 (Pubitemid 36637912)
20. Cole S. L., Vassar R., BACE1 structure and function in health and Alzheimer's disease. Current Alzheimer Research 2008 5 2 100 120 2-s2.0-42149130900 10.2174/156720508783954758 (Pubitemid 351536336)
21. Tanzi R. E., Bertram L., Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005 120 4 545 555 2-s2.0-13944276825 10.1016/j.cell.2005.02.008 (Pubitemid 40269768)
22. Zou L., Yang R., Zhang P., Dai Y., The enhancement of amyloid precursor protein and β -site amyloid cleavage enzyme 1 interaction: amyloid- β production with aging. International Journal of Molecular Medicine 2010 25 3 401 407 2-s2.0-76949086087 10.3892/ijmm-00000358
23. Sheng R., Lin X., Zhang J., Chol K. S., Huang W., Yang B., He Q., Hu Y., Design, synthesis and evaluation of flavonoid derivatives as potent AChE inhibitors. Bioorganic & Medicinal Chemistry 2009 17 18 6692 6698 2-s2.0-69249148311 10.1016/j.bmc.2009.07.072
24. Bottegoni G., Favia A. D., Recanatini M., Cavalli A., The role of fragment-based and computational methods in polypharmacology. Drug Discovery Today 2012 17 1-2 23 34 2-s2.0-84855849188 10.1016/j.drudis.2011.08.002
25. Breitenlechner C. B., Wegge T., Berillon L., Graul K., Marzenell K., Friebe W.-G., Thomas U., Schumacher R., Huber R., Engh R. A., Masjost B., Structure-based optimization of novel azepane derivatives as PKB inhibitors. Journal of Medicinal Chemistry 2004 47 6 1375 1390 2-s2.0-12144287555 10.1021/jm0310479 (Pubitemid 38327465)
26. Luo Y., Shoemaker A. R., Liu X., Woods K. W., Thomas S. A., de Jong R., Han E. K., Li T., Stoll V. S., Powlas J. A., Oleksijew A., Mitten M. J., Shi Y., Guan R., McGonigal T. P., Klinghofer V., Johnson E. F., Leverson J. D., Bouska J. J., Mamo M., Smith R. A., Gramling-Evans E. E., Zinker B. A., Mika A. K., Nguyen P. T., Oltersdorf T., Rosenberg S. H., Li Q., Giranda V. L., Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Molecular Cancer Therapeutics 2005 4 6 977 986 2-s2.0-20344384859 10.1158/1535-7163.MCT-05-0005 (Pubitemid 40909080)
27. Deshpande S. K., Molecule fragmentation scheme and method for designing new molecules. Google Patents 2008
28. Verma J., Khedkar V. M., Coutinho E. C., 3D-QSAR in drug design-a review. Current Topics in Medicinal Chemistry 2010 10 1 95 115 2-s2.0-77949342214 10.2174/156802610790232260
29. VLifeMDS: Molecular Design Suite 2004 3rd Pune, India Vlife Sciences Technologies Pvt. Ltd.
30. Baumann K., An alignment-independent versatile structure descriptor for QSAR and QSPR based on the distribution of molecular features. Journal of Chemical Information and Computer Sciences 2002 42 1 26 35 2-s2.0-0036025430 10.1021/ci990070t (Pubitemid 35359022)
31. Ajmani S., Kulkarni S. A., Application of GQSAR for scaffold hopping and lead optimization in multitarget inhibitors. Molecular Informatics 2012 31 6-7 473 490
32. Cramer R. D. III, Patterson D. E., Bunce J. D., Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. Journal of the American Chemical Society 1988 110 18 5959 5967 2-s2.0-0023751431
33. Afantitis A., Melagraki G., Sarimveis H., Igglessi-Markopoulou O., Kollias G., A novel QSAR model for predicting the inhibition of CXCR3 receptor by 4-N-aryl-[1,4] diazepane ureas. European Journal of Medicinal Chemistry 2009 44 2 877 884 2-s2.0-60149104848 10.1016/j.ejmech.2008.05.028
34. Golbraikh A., Tropsha A., Beware of q2! Journal of Molecular Graphics and Modelling 2002 20 4 269 276 2-s2.0-0036006911 10.1016/S1093-3263(01)00123-1 (Pubitemid 34017544)
35. www.rcsb.org/pdb
36. Schrodinger, Schrodinger suite. LLC, New York, NY, USA, 2009
37. Wallace A. C., Laskowski R. A., Thornton J. M., LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Engineering 1995 8 2 127 134 2-s2.0-0028922586
38. Nayyar A., Monga V., Malde A., Coutinho E., Jain R., Synthesis, anti-tuberculosis activity, and 3D-QSAR study of 4-(adamantan-1-yl)-2- substituted quinolines. Bioorganic and Medicinal Chemistry 2007 15 2 626 640 2-s2.0-33845321975 10.1016/j.bmc.2006.10.064 (Pubitemid 44880735)
39. Pal D., Sengupta C., De A., A new topochemical descriptor (TAU) in molecular connectivity concept: part I-aliphatic compounds. Indian Journal of Chemistry B 1988 27 734 739
40. Pal D. K., Sengupta C., De A. U., Introduction of a novel topochemical index and exploitation of group connectivity concept to achieve predictability in QSAR and RDD. Indian Journal of Chemistry B 1989 28 3 261 267 2-s2.0-0024322978 (Pubitemid 19199247)
41. Roy K., Das R. N., On some novel extended topochemical atom (ETA) parameters for effective encoding of chemical information and modelling of fundamental physicochemical properties. SAR and QSAR in Environmental Research 2011 22 5-6 451 472 2-s2.0-80051816061 10.1080/1062936X.2011.569900
42. Roy K., Ghosh G., Exploring QSARs with Extended Topochemical Atom (ETA) indices for modeling chemical and drug toxicity. Current Pharmaceutical Design 2010 16 24 2625 2639 2-s2.0-77957967208 10.2174/138161210792389270
43. Hall L. H., Kier L. B., The molecular connectivity chi indexes and kappa shape indexes in structure-property modeling. Reviews in Computational Chemistry 1991 2 367 422 10.1002/9780470125793.ch9